MAPK

[Leukemia] Spred1 knockout, regardless if occurred in HSCs or in endothelial cells, increased miR-126 in Lin−Sca-1+c-Kit+, a population enriched in leukemic stem cells (LSCs), resulting in expansion of LSCs, likely through hyperactivation of the MAPK/ERK pathway that augmented Bcl-2 expression and stability.

[World Journal of Microbiology & Biotechnology] Scientists explored the anticancer activity and its underlying mechanisms of PPT in HCT116 cells. The MTT assay was used to monitor the cell viability.

[Aging] Scientists screened rutin (RT) for its activity against osteoarthritis with in vivo and in vitro models of osteoarthritis. Pretreatment of RT decreased the ECM degradation, inhibited expression of TRAF-6 and BCL-2 the NF-κB/MAPK pathway proteins.

[Erasca, Inc.] Erasca, Inc. announced dosing of the first patient in HERKULES-3, a Phase Ib/II master protocol clinical trial evaluating ERAS-007 in combination with various agents in patients with gastrointestinal cancer, with initial focus on patients with advanced colorectal cancer.

[NPJ Regenerative Medicine] Using SPRY4 gene delivery into healthy and degenerated chondrocytes, investigators elucidated the role of SPRY4 in preventing chondrocyte hypertrophy. In addition to using the human cartilage tissues with the destabilization of the model in Sprague-Dawley rats, the role of SPRY4 in cartilage tissues and chondrocytes was explored through their molecular and histological analysis.

[Future Medicinal Chemistry] To outline the inhibitory role of HIC on prostate cancer cells, PC-3 and DU145 cell lines were treated with the respective IC50 concentrations, which reduced cell proliferation, adherence properties and spheroid formation.